JPH01233218A - Vitamin composition - Google Patents
Vitamin compositionInfo
- Publication number
- JPH01233218A JPH01233218A JP5924288A JP5924288A JPH01233218A JP H01233218 A JPH01233218 A JP H01233218A JP 5924288 A JP5924288 A JP 5924288A JP 5924288 A JP5924288 A JP 5924288A JP H01233218 A JPH01233218 A JP H01233218A
- Authority
- JP
- Japan
- Prior art keywords
- capsule
- adjuvant
- vitamin
- fat
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940088594 vitamin Drugs 0.000 title claims abstract description 41
- 229930003231 vitamin Natural products 0.000 title claims abstract description 41
- 235000013343 vitamin Nutrition 0.000 title claims abstract description 41
- 239000011782 vitamin Substances 0.000 title claims abstract description 41
- 150000003722 vitamin derivatives Chemical class 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000002671 adjuvant Substances 0.000 claims abstract description 22
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229940049964 oleate Drugs 0.000 claims abstract description 11
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 claims abstract description 10
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 claims abstract description 9
- 239000001087 glyceryl triacetate Substances 0.000 claims abstract description 9
- 235000013773 glyceryl triacetate Nutrition 0.000 claims abstract description 9
- 229940042585 tocopherol acetate Drugs 0.000 claims abstract description 9
- 229960002622 triacetin Drugs 0.000 claims abstract description 9
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 9
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 9
- 229920000053 polysorbate 80 Polymers 0.000 claims description 9
- 229940068968 polysorbate 80 Drugs 0.000 claims description 9
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract description 12
- 239000007901 soft capsule Substances 0.000 abstract description 11
- 235000005152 nicotinamide Nutrition 0.000 abstract description 6
- 239000011570 nicotinamide Substances 0.000 abstract description 6
- 230000002542 deteriorative effect Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- 150000004667 medium chain fatty acids Chemical class 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- -1 butyrate ester Chemical class 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000209094 Oryza Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 208000010798 Tongue disease Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は、水溶性ビタミンと脂溶性ビタミンを同時に含
有する軟カプセルに関するものであり、さらに詳しくは
、水溶性ビタミンとしてニコチン酸アミド、脂溶性ビタ
ミンとして酪酸リボフラビンと酢酸トコフェロールとγ
−オリザノールを配合した脂溶性ビタミン組成物に関す
るものである。[Detailed Description of the Invention] [Field of Industrial Application] The present invention relates to a soft capsule containing water-soluble vitamins and fat-soluble vitamins at the same time. Riboflavin butyrate and tocopherol acetate and gamma as vitamins
-This invention relates to a fat-soluble vitamin composition containing oryzanol.
［従来の技術］
ニコチン酸アミドは、水溶性ビタミンで、欠乏症にはベ
ラグラや犬の黒舌病が知られ、その他各粘膜もおかされ
、食欲減退・消化不良・下痢・貧血・神経障害・生殖障
害などを起す。[Conventional technology] Nicotinamide is a water-soluble vitamin, and deficiencies include veragra and canine black tongue disease, and other mucous membranes are also affected, resulting in loss of appetite, indigestion, diarrhea, anemia, neurological disorders, and reproduction. Causes problems etc.
酪酸リボフラビン（ビタミンＢ２）は、水溶性のビタミ
ンであるリボフラビンの酪酸エステルであり、そのリボ
フラビンは動物の生長促進性ビタミンとして、古くから
知られていた。我が国民の食物にはＢ２が一般に不足し
、食品の８２強化が行われている。Riboflavin butyrate (vitamin B2) is a butyrate ester of riboflavin, which is a water-soluble vitamin, and riboflavin has long been known as a growth-promoting vitamin in animals. There is generally a lack of B2 in the food of our people, and 82 fortification of foods is being carried out.
ｄｌ−α酢酸トコフェロールは、脂溶性ビタミンで、小
麦や米のハイ芽油中に多く含まれ、欠乏症になると、性
欲消失・精子消失・不妊症・流産など繁殖に関して重要
なだけでなく、生長・神経作用にも重要なビタミンで、
ある。dl-α tocopherol acetate is a fat-soluble vitamin that is abundantly contained in the high sprout oil of wheat and rice, and when it is deficient, it is not only important for reproduction, such as loss of libido, loss of sperm, infertility, and miscarriage, but also for growth and A vitamin that is also important for nerve function.
be.
γ−オリザノールも脂溶性ビタミンの一種で、米ヌカ油
やハイ芽油中の不ケン化物から取り出され、間脳視床下
部の性中枢の老化防止、精神安定、ならびに一般の若返
りに有効である。γ-Oryzanol is also a type of fat-soluble vitamin, which is extracted from unsaponifiables in rice bran oil and high sprout oil, and is effective in preventing aging of the sex center of the diencephalic hypothalamus, stabilizing the mind, and general rejuvenation.
従来、上述の様なビタミンを食品栄養補助剤として、個
別或は同時に含有する製剤をソフトカプセル（ゼラチン
カプセル）にして供給する試みが数多くなされてきた。Conventionally, many attempts have been made to supply formulations containing the above-mentioned vitamins individually or simultaneously as soft capsules (gelatin capsules) as food nutritional supplements.
ゼラチンソフトカプセルはその性質上（水と出会うと溶
解する）、おもに脂溶性のビタミン共与体として数多く
使用され、その補助剤も各種ビタミンに応じて数多くの
試みが成されてきた。Due to their nature (they dissolve when they come into contact with water), gelatin soft capsules are often used primarily as fat-soluble vitamin conjugates, and many attempts have been made to use them as adjuvants for various vitamins.
例えば、特開昭５８−２０８２１５号では、脂溶性ビタ
ミンであるビタミンＢ２酪酸エステルに補助剤としてグ
リセリン脂肪酸エステルを配合したものが提案されてい
る。For example, Japanese Patent Application Laid-Open No. 58-208215 proposes a composition in which glycerin fatty acid ester is blended with vitamin B2 butyrate, which is a fat-soluble vitamin, as an adjuvant.
［発明が解決しようとする課題］
各種ビタミンの一日当りの摂取量は数ｍｇから数百ｍｇ
であり、各種ビタミンを個別に摂取することは服用の不
快感、煩多感を引き起こしていた。[Problem to be solved by the invention] The daily intake of various vitamins ranges from several mg to several hundred mg.
Therefore, taking various vitamins individually causes discomfort and bothersomeness when taking them.
しかし、上記ビタミンを同一のカプセルに保持させよう
とする場合、上記ニコチン酸アミドは、水溶性のビタミ
ンであり、その油剤に対する溶解性は微々たるものであ
り、上記脂溶性ビタミンである酪酸リボフラビン、ｄｉ
−α酢酸トコフェロールモしてγ−オリザノールとは、
従来の補助剤では溶解状態で同時に含有さ、れず、軟カ
プセルに充填すると結晶が析出して軟カプセルが不透明
となったり、商品価値が著しく低下する問題が生じてい
た。However, when trying to hold the above vitamins in the same capsule, the nicotinamide is a water-soluble vitamin and its solubility in oil is negligible, and the fat-soluble vitamin riboflavin butyrate, di
-α-tocopherol acetate and γ-oryzanol are:
Conventional adjuvants are not contained simultaneously in a dissolved state, and when filled into soft capsules, crystals precipitate, making the soft capsules opaque and causing problems such as a significant decrease in commercial value.
本発明者らは、水溶性ビタミンとしてニコチン酸アミド
、脂溶性ビタミンとして酪酸リボフラビンと酢酸トコフ
ェロールとγ−オリザノールを配合し、補助剤の組成物
とその配合量を種々変化させ、長期保存中でも結晶が析
出しない脂溶性ビタミン組成物を得ることを目的として
本発明に至った。The present inventors blended nicotinamide as a water-soluble vitamin and riboflavin butyrate, tocopherol acetate, and γ-oryzanol as fat-soluble vitamins, and varied the composition and amount of adjuvants to prevent crystallization even during long-term storage. The present invention was accomplished with the aim of obtaining a fat-soluble vitamin composition that does not precipitate.
［課題を解決するための手段］
本発明に係るビタミン組成物では、補助剤として、ポリ
ソルベート８０を３０〜５５％、プロピレングリコール
オレイン酸エステル及びトリアセチンの合計を１０〜４
０％を使用し、ニコチン酸アミド、酪酸リボフラビン、
酢酸トコフェロール、γ−オリザノールを同時に溶解配
合したものである。[Means for Solving the Problems] In the vitamin composition according to the present invention, as adjuvants, polysorbate 80 is contained in an amount of 30 to 55%, and the total amount of propylene glycol oleate and triacetin is 10 to 4%.
Using 0%, nicotinamide, riboflavin butyrate,
Tocopherol acetate and γ-oryzanol are dissolved and blended at the same time.
［作用］
補助剤として、ポリソルベート８０及びプロピレングリ
コールオレイン酸エステルという界面活性剤と溶剤であ
るトリアセチンを使用するため、脂溶性ビタミンと水溶
性ビタミンとが同時に溶解状態として存在することが可
能となる。[Function] Since surfactants such as polysorbate 80 and propylene glycol oleate and triacetin as a solvent are used as adjuvants, it is possible for fat-soluble vitamins and water-soluble vitamins to exist simultaneously in a dissolved state.
［実施例］
１カプセル中、水溶性ビタミンとしてニコヂン酸アミド
１２ｍｇ、脂溶性ビタミンとして酪酸リボフラビン６
Ｂ、酢酸トコフｌロール１００ ｍｇ、γ−オリザノー
ル５ｍｇを配合するようにし、補助剤の組成物とその配
合量を種々変化させた。[Example] One capsule contains 12 mg of nicodinamide as a water-soluble vitamin and 6 riboflavin butyrate as a fat-soluble vitamin.
B. 100 mg of tocoflole acetate and 5 mg of γ-oryzanol were blended, and the composition of the adjuvant and its blending amount were varied.
調整方法は、酢酸トコフェロールと補助剤を混合し、順
次、酪酸リボフラビン、ニコチン酸アミド、γ−オリザ
ノールを加え、７０℃で３０分間攪拌溶解させ、溶解し
たものはソフトカプセルを作成した。The preparation method involved mixing tocopherol acetate and an adjuvant, adding riboflavin butyrate, nicotinic acid amide, and γ-oryzanol sequentially, stirring and dissolving at 70° C. for 30 minutes, and making soft capsules from the dissolved product.
その後、該ソフトカプセルを室温及び４℃の条件下で保
存し、その経時的安定性を判定した。Thereafter, the soft capsules were stored at room temperature and 4° C., and their stability over time was determined.
以下に、比較例及び実施例を示す。Comparative examples and examples are shown below.
（比較例１）
補助剤としてトリアセチンを使用し、１カプセルの全量
を３３０ｍｍになるようにした。(Comparative Example 1) Triacetin was used as an adjuvant, and the total volume of one capsule was adjusted to 330 mm.
（比較例２）
補助剤として中鎖脂肪酸トリグリセライドを使用し、１
カプセルの全量を３３０ｍｍになるようにした。(Comparative Example 2) Using medium chain fatty acid triglyceride as an adjuvant, 1
The total length of the capsule was set to 330 mm.
なお、本比較例で使用した中鎖脂肪酸トリグリセライド
は、次式；
で表わされるものを使用した。The medium chain fatty acid triglyceride used in this comparative example was represented by the following formula:
（比較例３）
補助剤としてポリソルベート８０を使用し、１カプセル
の全量を３３０ｍｍになるようにした。(Comparative Example 3) Polysorbate 80 was used as an adjuvant, and the total volume of one capsule was adjusted to 330 mm.
（比較例４）
補助剤としてプロピレングリコールオレイン酸エステル
を使用し、１カプセルの全量を３３０ｍ１ｉになるよう
にした。(Comparative Example 4) Propylene glycol oleate was used as an adjuvant, and the total amount of one capsule was adjusted to 330 m1i.
（比較例５）
補助剤としてトリアセチン（１００ｍｇ／ｌカプセル）
とプロピレングリコールオレイン酸エステル（１０７ｍ
ｇ／ｌカプセル）を使用し、１カプセルの全量を３３０
ｍｍになるようにした。(Comparative Example 5) Triacetin (100 mg/l capsule) as an adjuvant
and propylene glycol oleate (107m
g/l capsule), and the total amount of 1 capsule is 330 g/l.
It was set to mm.
（比較例６）
補助剤として中鎖脂肪酸トリグリセライド（１００ｍｇ
／ｌカプセル）とプロピレングリコールオレイン酸エス
テル（ｔｏ７ｍｇ／ｌカプセル）を使用し、ｌカプセル
の全量を３３０ｍｍになるようにした。(Comparative Example 6) Medium chain fatty acid triglyceride (100mg) as an adjuvant
/l capsule) and propylene glycol oleate (to7mg/l capsule) were used, and the total volume of the l capsule was adjusted to 330 mm.
（比較例７）
補助剤としてトリアセチン（６９ｍｇ／ｌカプセル）と
ポリソルベート８０（６９ｍｇ／ｌカプセル）とプロピ
レングリコールオレイン酸エステル（６９ｍｇ／ｌカプ
セル）を使用し、１カプセルの全量を３３０ｍｍになる
ようにした。(Comparative Example 7) Triacetin (69 mg/l capsule), polysorbate 80 (69 mg/l capsule), and propylene glycol oleate (69 mg/l capsule) were used as adjuvants, and the total volume of one capsule was adjusted to 330 mm. did.
（比較例８）
補助剤として中鎖脂肪酸トリグリセライド（６９ｍｇ／
ｌカプセル）とポリソルベート８０（６９ｍｇ／ｌカプ
セル）とプロピレングリコールオレイン酸エステル（６
９ｍｇ／ｌカプセル）を使用し、１カプセルの全量を３
３０ｍｍになるようにした。(Comparative Example 8) Medium chain fatty acid triglyceride (69mg/
polysorbate 80 (69 mg/l capsule) and propylene glycol oleate (69 mg/l capsule)
9mg/l capsule), and the total amount of 1 capsule is 3
I set it to 30mm.
上記、比較例１から比較例８の結果を表１に示す。Table 1 shows the results of Comparative Examples 1 to 8 above.
（実施例１）
比較例と同様に、補助剤としてポリソルベート８０（１
４６ｍｇ／ｌカプセル）とプロピレングリコールオレイ
ン酸エステル（６１ｍｇ／ｌカプセル）を使用し、１カ
プセルの全量を３３０ｍｍになるようにした。(Example 1) Similarly to the comparative example, polysorbate 80 (1
46 mg/l capsule) and propylene glycol oleate (61 mg/l capsule) were used, and the total volume of one capsule was 330 mm.
（実施例２）
補助剤としてトリアセチン（１８０／１カプセル）とポ
リソルベート８０（１４７ｍｇ／ｌカプセル）を使用し
、１カプセルの全量を４５０ｍｍになるようにした。(Example 2) Triacetin (180/1 capsule) and polysorbate 80 (147 mg/l capsule) were used as adjuvants, and the total volume of one capsule was adjusted to 450 mm.
（実施例３）
補助剤としてトリアセチン（１０／１カプセル）とポリ
ソルベート８０（１３７ｍｇ／ｌカプセル）プロピレン
グリコールオレイン酸エステル（６０ｍｇ／ｌカプセル
）を使用し、１カプセルの全量を３３０ｍｍになるよう
にした。(Example 3) Triacetin (10/1 capsule), polysorbate 80 (137 mg/l capsule), and propylene glycol oleate (60 mg/l capsule) were used as adjuvants, and the total volume of one capsule was adjusted to 330 mm. .
実施例１から実施例３の結果を表２に示す。Table 2 shows the results of Examples 1 to 3.
表２に示すように、本実施例による補助剤の組成では上
記水溶性及び脂溶性ビタミンが溶解状態で保持され、３
力月間その状態に変化がなかった。As shown in Table 2, the composition of the adjuvant according to this example maintains the water-soluble and fat-soluble vitamins in a dissolved state;
There was no change in the condition for months.
本願発明によるビタミン組成物で、水溶性及び脂溶性の
ビタミンを溶解状態で同時に含有可能であり、軟カプセ
ルに充填すると結晶が析出して軟カプセルが不透明とな
ったり、商品価値が低下せず、しかも服用の不快感、煩
多感もない軟カプセルを得られる。The vitamin composition according to the present invention can simultaneously contain water-soluble and fat-soluble vitamins in a dissolved state, and when filled into soft capsules, crystals will not precipitate and the soft capsules will not become opaque or the commercial value will decrease. Furthermore, soft capsules can be obtained without discomfort or bothersome feeling when taking them.
［発明の効果］
本発明は以上説明したとおり、水溶性のビタミンである
ニコチン酸アミドと脂溶性のビタミンである酪酸リボフ
ラビン、ｄｉ−α酢酸トコフェロール、γ−オリザノー
ルを同時に配合し、溶解可能で経時的に析出がないため
、各ビタミンを個別に摂取する必要がなく商品価値の阻
害もないという効果がある。[Effects of the Invention] As explained above, the present invention simultaneously blends nicotinamide, which is a water-soluble vitamin, and riboflavin butyrate, which is a fat-soluble vitamin, di-α tocopherol acetate, and γ-oryzanol, so that they can dissolve over time. Since there is no precipitation, there is no need to take each vitamin individually, and there is no impact on commercial value.
代理人 弁理士 佐 藤 正 年Agent: Patent Attorney Tadashi Sato
Claims (1)
プロピレングリコールオレイン酸エステル及びトリアセ
チンの合計を１０〜４０％を使用し、ニコチン酸アミド
、酪酸リボフラビン、酢酸トコフェロール、γ−オリザ
ノールを同時に溶解配合したことを特徴とするビタミン
組成物。As an adjuvant, 30-55% polysorbate 80,
A vitamin composition characterized in that a total of 10 to 40% of propylene glycol oleate and triacetin is used, and nicotinamide, riboflavin butyrate, tocopherol acetate, and γ-oryzanol are simultaneously dissolved and blended.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5924288A JPH01233218A (en) | 1988-03-15 | 1988-03-15 | Vitamin composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5924288A JPH01233218A (en) | 1988-03-15 | 1988-03-15 | Vitamin composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH01233218A true JPH01233218A (en) | 1989-09-19 |
Family
ID=13107724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5924288A Pending JPH01233218A (en) | 1988-03-15 | 1988-03-15 | Vitamin composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH01233218A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5532002A (en) * | 1989-08-17 | 1996-07-02 | Cortecs Limited | Gelatin pharmaceutical formulations |
| US5738871A (en) * | 1989-08-17 | 1998-04-14 | Cortecs Limited | Pharmaceutical formulations |
-
1988
- 1988-03-15 JP JP5924288A patent/JPH01233218A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5532002A (en) * | 1989-08-17 | 1996-07-02 | Cortecs Limited | Gelatin pharmaceutical formulations |
| US5738871A (en) * | 1989-08-17 | 1998-04-14 | Cortecs Limited | Pharmaceutical formulations |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3950547A (en) | Dietary composition and methods of preparing | |
| US4497800A (en) | Stable liquid diet composition | |
| DE69821359T2 (en) | TASTEFUL ELEMENTARY MEDICAL FOOD | |
| US4368204A (en) | Nutrition composition for pediatrics | |
| US10285965B2 (en) | Method for supplementing and administering a concentrated liquid diet | |
| JP5473330B2 (en) | Infant formulations containing docosahexaenoic acid and lutein | |
| JP2675560B2 (en) | Nutritional composition having physiological activity | |
| US3701666A (en) | Process for making amino acid composition | |
| MXPA06013676A (en) | Nutritional formulations. | |
| WO1993006834A1 (en) | Enteral preparation for cancer therapy | |
| JPH1179987A (en) | Composition for suppressing accumulation of hepatic fat and food additive for suppressing accumulation of hepatic fat | |
| JP2000106844A (en) | Water-dispersible carotenoid composition | |
| JP2005002005A (en) | Coenzyme q10-containing composition | |
| Schaeffer et al. | Cataract development in animals with delayed supplementation of tryptophane | |
| EP0127297B1 (en) | Vitamin composition with enhanced bioavailability and method of administering same | |
| JPH01233218A (en) | Vitamin composition | |
| JPH05111366A (en) | Nutrient-controlled food | |
| JP2005047851A (en) | Ubidecarenone-containing composition | |
| JP2000325040A (en) | Learning/memory capacity-improving food | |
| JP2007074937A (en) | Coenzyme q10-enriched egg, method for producing the same, and blended feed for poultry | |
| US11350657B2 (en) | Protein gummy composition | |
| JP2769587B2 (en) | Powder nutrition composition | |
| JPH10139681A (en) | Aqueous emulsified nutritional composition and its use | |
| JP6080508B2 (en) | Postoperative meal | |
| JP2005350371A (en) | Nutrient composition for hepatopathic patient |